Nephros | 4: Statement of changes in beneficial ownership of securities-Director Amron Arthur H
Nephros | 8-K: Current report
Nephros | EFFECT: Others
Nephros | 4: Statement of changes in beneficial ownership of securities-Officer Banks Robert R. Jr.
Nephros | 4: Statement of changes in beneficial ownership of securities-Director Amron Arthur H
Nephros | 4: Statement of changes in beneficial ownership of securities-Director Lask Alisa
Nephros | 4: Statement of changes in beneficial ownership of securities-Director Harris Joseph Michael
Nephros | 4: Statement of changes in beneficial ownership of securities-Director Spandow Oliver J.
Nephros | S-3: Registration statement for specified transactions by certain issuers
Nephros | 10-Q: Quarterly report
Nephros | 8-K: Nephros Announces Financial Results for Quarter Ended March 31, 2024 First-Quarter Net Revenue of $3.5 Million; Technology advancements and microplastics capabilities on the horizon
Nephros | 8-K: Current report
Nephros | ARS: Annual Report to Security Holders
Nephros | DEFA14A: Others
Nephros | DEF 14A: Definitive information statements
Nephros | 10-K: Annual report
Nephros | 4: Statement of changes in beneficial ownership of securities-10% Owner WEXFORD CAPITAL LP
Nephros | 4: Statement of changes in beneficial ownership of securities-Director Amron Arthur H
Nephros | 8-K: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million
Nephros | 4: Statement of changes in beneficial ownership of securities-Director Spandow Oliver J.
No Data